Employees Retirement System of Texas Has $2.17 Million Stake in Icon Plc $ICLR

Employees Retirement System of Texas trimmed its holdings in Icon Plc (NASDAQ:ICLR) by 94.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,901 shares of the medical research company’s stock after selling 216,622 shares during the period. Employees Retirement System of Texas’ holdings in Icon were worth $2,169,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in Icon by 26.6% during the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after purchasing an additional 975,268 shares during the last quarter. Invesco Ltd. lifted its holdings in Icon by 11.1% during the 3rd quarter. Invesco Ltd. now owns 3,427,630 shares of the medical research company’s stock worth $599,835,000 after purchasing an additional 341,637 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Icon by 739.2% during the 3rd quarter. Principal Financial Group Inc. now owns 3,277,293 shares of the medical research company’s stock worth $573,526,000 after purchasing an additional 2,886,755 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Icon by 35.4% during the 3rd quarter. Franklin Resources Inc. now owns 2,753,528 shares of the medical research company’s stock worth $481,692,000 after purchasing an additional 719,301 shares during the last quarter. Finally, Ruane Cunniff & Goldfarb L.P. lifted its holdings in Icon by 36.2% during the 2nd quarter. Ruane Cunniff & Goldfarb L.P. now owns 1,708,183 shares of the medical research company’s stock worth $248,455,000 after purchasing an additional 453,833 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Price Performance

Icon stock opened at $118.45 on Thursday. The stock’s fifty day moving average price is $111.55 and its two-hundred day moving average price is $141.66. Icon Plc has a one year low of $66.57 and a one year high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market cap of $9.57 billion, a PE ratio of 16.03, a price-to-earnings-growth ratio of 2.97 and a beta of 1.23.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.52 EPS for the quarter, missing analysts’ consensus estimates of $3.14 by ($0.62). Icon had a return on equity of 10.58% and a net margin of 7.40%.The company had revenue of $2.11 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter last year, the business earned $3.43 EPS. Icon’s revenue was up 2.5% on a year-over-year basis. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. As a group, research analysts expect that Icon Plc will post 11.53 EPS for the current fiscal year.

Analyst Ratings Changes

ICLR has been the subject of several research reports. JPMorgan Chase & Co. dropped their price target on Icon from $175.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, May 18th. Jefferies Financial Group set a $135.00 price target on Icon and gave the stock a “buy” rating in a report on Monday, February 23rd. Citigroup dropped their price target on Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a report on Wednesday, March 11th. Leerink Partners set a $125.00 price target on Icon in a report on Monday, May 4th. Finally, Weiss Ratings cut Icon from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $147.67.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.